This study quantitatively assesses metabolic memory by modeling the relationship between hyperglycemic exposure and renal function decline in patients with type 2 diabetes (T2D).
Methods
This retrospective longitudinal study included 381 Japanese patients with T2D. Hyperglycemic exposure was presented by calculating the area under the curve (AUC) for HbA1c ≥ 6 % (AUCHbA1c ≥ 6 %) during the observation period. A non-linear mixed-effects model was constructed to predict changes in estimated glomerular filtration rate (eGFR) based on AUCHbA1c ≥ 6 %.
Results
The relationship between AUCHbA1c ≥ 6 % and eGFR changes was shown by a sigmoidal curve, with sex, age, diabetic retinopathy, dyslipidemia, and hypertension incorporated as covariates. The predictive utility of the model was validated using goodness-of-fit plot, visual predictive check, and bootstrap methods.
Conclusions
We developed an AUCHbA1c ≥ 6 %-based model to predict renal function decline in patients with T2D, showing that AUCHbA1c ≥ 6 % may serve as a quantitative indicator of metabolic memory.
{"title":"Quantitative assessment of metabolic memory and its prediction of renal function decline in patients with type 2 diabetes: A retrospective observational study","authors":"Kentaro Oniki , Takuro Shigaki , Ayami Kajiwara-Morita , Keiichi Shigetome , Akira Yoshida , Hideaki Jinnouchi , Junji Saruwatari","doi":"10.1016/j.dsx.2025.103225","DOIUrl":"10.1016/j.dsx.2025.103225","url":null,"abstract":"<div><h3>Aims</h3><div>This study quantitatively assesses metabolic memory by modeling the relationship between hyperglycemic exposure and renal function decline in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>This retrospective longitudinal study included 381 Japanese patients with T2D. Hyperglycemic exposure was presented by calculating the area under the curve (AUC) for HbA1c ≥ 6 % (AUC<sub>HbA1c ≥ 6 %</sub>) during the observation period. A non-linear mixed-effects model was constructed to predict changes in estimated glomerular filtration rate (eGFR) based on AUC<sub>HbA1c ≥ 6 %</sub>.</div></div><div><h3>Results</h3><div>The relationship between AUC<sub>HbA1c ≥ 6 %</sub> and eGFR changes was shown by a sigmoidal curve, with sex, age, diabetic retinopathy, dyslipidemia, and hypertension incorporated as covariates. The predictive utility of the model was validated using goodness-of-fit plot, visual predictive check, and bootstrap methods.</div></div><div><h3>Conclusions</h3><div>We developed an AUC<sub>HbA1c ≥ 6 %</sub>-based model to predict renal function decline in patients with T2D, showing that AUC<sub>HbA1c ≥ 6 %</sub> may serve as a quantitative indicator of metabolic memory.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103225"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103240
Ningjian Wang , Anoop Misra
{"title":"Highlights of the current issue","authors":"Ningjian Wang , Anoop Misra","doi":"10.1016/j.dsx.2025.103240","DOIUrl":"10.1016/j.dsx.2025.103240","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103240"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144184439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103237
Subhasis Neogi , Madhurima Basu , Pradip Mukhopadhyay , Arpita Ray Chaudhury , Nitai P. Bhattacharyya , Sujoy Ghosh
Aims
This study was undertaken to evaluate differences in composite renal outcomes between diabetic kidney disease (DKD) and non-diabetic kidney disease (NDKD) (prospectively performed, biopsy proven), along with predictors of renal outcome in subjects with DKD.
Methods
A composite renal outcome comprising of doubling of creatinine, end stage renal disease (ESRD) or renal death was documented in biopsy proven DKD and NDKD subjects. Differences in outcome (DKD vs. NDKD) were compared. Clinical, biochemical and histopathological parameters were evaluated as possible predictors of composite renal outcome in DKD.
Results
91 subjects (72 DKD and 19 NDKD) were included for analysis. The hazard ratio (HR) for composite renal outcome was 0.27 (0.08–0.9) (p = 0.03) in favour of NDKD. Kaplan-Meier analysis demonstrated NDKD subjects had better composite renal outcome compared to DKD (log rank chi-square 6.69, p = 0.009). Degree of proteinuria and renal pathology society (RPS) class (III/IV) predicted worse outcome in those with DKD.
Conclusions
Composite renal outcomes in NDKD was better as compared to those with DKD. RPS class III/IV on histopathology and degree of proteinuria was associated with poorer composite renal outcome in patients with DKD.
{"title":"Composite renal outcome in prospectively performed biopsy proven diabetic kidney disease versus non-diabetic kidney disease: A longitudinal follow up","authors":"Subhasis Neogi , Madhurima Basu , Pradip Mukhopadhyay , Arpita Ray Chaudhury , Nitai P. Bhattacharyya , Sujoy Ghosh","doi":"10.1016/j.dsx.2025.103237","DOIUrl":"10.1016/j.dsx.2025.103237","url":null,"abstract":"<div><h3>Aims</h3><div>This study was undertaken to evaluate differences in composite renal outcomes between diabetic kidney disease (DKD) and non-diabetic kidney disease (NDKD) (prospectively performed, biopsy proven), along with predictors of renal outcome in subjects with DKD.</div></div><div><h3>Methods</h3><div>A composite renal outcome comprising of doubling of creatinine, end stage renal disease (ESRD) or renal death was documented in biopsy proven DKD and NDKD subjects. Differences in outcome (DKD vs. NDKD) were compared. Clinical, biochemical and histopathological parameters were evaluated as possible predictors of composite renal outcome in DKD.</div></div><div><h3>Results</h3><div>91 subjects (72 DKD and 19 NDKD) were included for analysis. The hazard ratio (HR) for composite renal outcome was 0.27 (0.08–0.9) (p = 0.03) in favour of NDKD. Kaplan-Meier analysis demonstrated NDKD subjects had better composite renal outcome compared to DKD (log rank chi-square 6.69, p = 0.009). Degree of proteinuria and renal pathology society (RPS) class (III/IV) predicted worse outcome in those with DKD.</div></div><div><h3>Conclusions</h3><div>Composite renal outcomes in NDKD was better as compared to those with DKD. RPS class III/IV on histopathology and degree of proteinuria was associated with poorer composite renal outcome in patients with DKD.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103237"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103228
Xiao Liu , Jitao Ling , Yifan Wu , Huilei Zhao , Yuzhe Hu , Zhiwei Yan , Wengen Zhu , Peng Yu , Jinfeng Wang , Yuling Zhang , Tommaso Bucci , Gregory Y.H. Lip
Introduction
Obesity is not a single diagnosis, and the association of ‘metabolically unhealthy’ obesity with cardiovascular disease is well-described. However, the relationship between metabolically healthy obesity (MHO) and atrial fibrillation (AF) is still debated.
Objective
Our objective is to investigate the association between MHO and the risk of AF.
Methods
A comprehensive search of databases, including PubMed, EMBASE, Web of Science, and the Cochrane Library regarding longitudinal studies of MHO and risk of AF was performed. Random effects were used to pool the effect estimates.
Results
Nine cohort studies comprising 4,250,557 participants were included. The pooled results revealed that individuals with MHO were associated with a greater incidence of AF than those with a metabolically healthy normal weight (HR: 1.34, 95 % CI: 1.26 to 1.42) with moderate certainty according to the Grading of Recommendations Assessment, Development, and Evaluation assessment. Individuals with MHO were associated with a lower risk of AF compared with participants with metabolically unhealthy obesity (RR: 0.48, 95 % CI: 0.36 to 0.64). Individuals with MHO were not significantly associated with the risk of AF as compared to metabolically unhealthy normal weight (HR: 1.04, 95 % CI: 0.89 to 1.22).
Conclusion
MHO is associated with a greater incidence of AF, highlighting the importance of weight reduction in individuals without metabolic disorders in reducing the risk of AF.
{"title":"Association between metabolically healthy obesity and atrial fibrillation: A systematic review and meta-analysis of longitudinal studies","authors":"Xiao Liu , Jitao Ling , Yifan Wu , Huilei Zhao , Yuzhe Hu , Zhiwei Yan , Wengen Zhu , Peng Yu , Jinfeng Wang , Yuling Zhang , Tommaso Bucci , Gregory Y.H. Lip","doi":"10.1016/j.dsx.2025.103228","DOIUrl":"10.1016/j.dsx.2025.103228","url":null,"abstract":"<div><h3>Introduction</h3><div>Obesity is not a single diagnosis, and the association of ‘metabolically unhealthy’ obesity with cardiovascular disease is well-described. However, the relationship between metabolically healthy obesity (MHO) and atrial fibrillation (AF) is still debated.</div></div><div><h3>Objective</h3><div>Our objective is to investigate the association between MHO and the risk of AF.</div></div><div><h3>Methods</h3><div>A comprehensive search of databases, including PubMed, EMBASE, Web of Science, and the Cochrane Library regarding longitudinal studies of MHO and risk of AF was performed. Random effects were used to pool the effect estimates.</div></div><div><h3>Results</h3><div>Nine cohort studies comprising 4,250,557 participants were included. The pooled results revealed that individuals with MHO were associated with a greater incidence of AF than those with a metabolically healthy normal weight (HR: 1.34, 95 % CI: 1.26 to 1.42) with moderate certainty according to the Grading of Recommendations Assessment, Development, and Evaluation assessment. Individuals with MHO were associated with a lower risk of AF compared with participants with metabolically unhealthy obesity (RR: 0.48, 95 % CI: 0.36 to 0.64). Individuals with MHO were not significantly associated with the risk of AF as compared to metabolically unhealthy normal weight (HR: 1.04, 95 % CI: 0.89 to 1.22).</div></div><div><h3>Conclusion</h3><div>MHO is associated with a greater incidence of AF, highlighting the importance of weight reduction in individuals without metabolic disorders in reducing the risk of AF.</div></div><div><h3>Registration</h3><div>PROSPERO - registration number CRD42023432195.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103228"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143882965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103238
Ramona Di Stefano , Lorenzo V. Rindi , Valentina Baldini , Rodolfo Rossi , Francesca Pacitti , Emmanuele A. Jannini , Alessandro Rossi
Aims
Suicide is a global public health concern, accounting for nearly 700,000 deaths annually. Although well-established risk factors, including mental health disorders, are widely recognized, emerging concerns have surfaced regarding a potential association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual Gastric Inhibitory Polypeptide (GIP)/GLP-1 Receptor Agonist tirzepatide and suicidal behavior. This systematic review aims to synthesize the available evidence on the potential association between these drugs and suicidal behavior.
Methods
This review was conducted following PRISMA guidelines. A systematic search was performed in MEDLINE, Embase, and APA PsycInfo up to September 24, 2024, using terms related to GLP-1 RAs/GIP/GLP-1 RAs and suicidal behavior.Three independent reviewers conducted article screening and data extraction. Risk of bias was evaluated using the Newcastle-Ottawa Scale for cohort studies and ROB2 for RCTs.
Results
The review identified 16 studies published between 2017 and 2024, consisting of 5 observational studies, 2 randomized controlled trials, 8 pharmacovigilance analyses, and 1 post-hoc analysis of RCTs. No consistent evidence indicated an increased suicide risk among GLP-1 RA users. Pharmacovigilance analyses produced mixed findings; while some disproportionality analyses reported higher rates relative to other antihyperglycemic drugs, no causal link was confirmed. Cohort studies involving diabetic and obese populations generally did not demonstrate a significant increase in suicidal behavior.
Conclusions
Although current data do not warrant changes in prescribing practices, further research is needed before definitive conclusions can be drawn. Moreover, the generalizability and reliability of these findings should be interpreted in light of the methodological limitations of the included studies.
{"title":"Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports","authors":"Ramona Di Stefano , Lorenzo V. Rindi , Valentina Baldini , Rodolfo Rossi , Francesca Pacitti , Emmanuele A. Jannini , Alessandro Rossi","doi":"10.1016/j.dsx.2025.103238","DOIUrl":"10.1016/j.dsx.2025.103238","url":null,"abstract":"<div><h3>Aims</h3><div>Suicide is a global public health concern, accounting for nearly 700,000 deaths annually. Although well-established risk factors, including mental health disorders, are widely recognized, emerging concerns have surfaced regarding a potential association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual Gastric Inhibitory Polypeptide (GIP)/GLP-1 Receptor Agonist tirzepatide and suicidal behavior. This systematic review aims to synthesize the available evidence on the potential association between these drugs and suicidal behavior.</div></div><div><h3>Methods</h3><div>This review was conducted following PRISMA guidelines. A systematic search was performed in MEDLINE, Embase, and APA PsycInfo up to September 24, 2024, using terms related to GLP-1 RAs/GIP/GLP-1 RAs and suicidal behavior.Three independent reviewers conducted article screening and data extraction. Risk of bias was evaluated using the Newcastle-Ottawa Scale for cohort studies and ROB2 for RCTs.</div></div><div><h3>Results</h3><div>The review identified 16 studies published between 2017 and 2024, consisting of 5 observational studies, 2 randomized controlled trials, 8 pharmacovigilance analyses, and 1 post-hoc analysis of RCTs. No consistent evidence indicated an increased suicide risk among GLP-1 RA users. Pharmacovigilance analyses produced mixed findings; while some disproportionality analyses reported higher rates relative to other antihyperglycemic drugs, no causal link was confirmed. Cohort studies involving diabetic and obese populations generally did not demonstrate a significant increase in suicidal behavior.</div></div><div><h3>Conclusions</h3><div>Although current data do not warrant changes in prescribing practices, further research is needed before definitive conclusions can be drawn. Moreover, the generalizability and reliability of these findings should be interpreted in light of the methodological limitations of the included studies.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103238"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103226
Anoop Misra
{"title":"Rational application of weight loss therapies according to new obesity guidelines in Asian Indians: A perspective for low-income settings","authors":"Anoop Misra","doi":"10.1016/j.dsx.2025.103226","DOIUrl":"10.1016/j.dsx.2025.103226","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103226"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.dsx.2025.103236
Ujjwal Das , Nishamani Kar , Tomo Riba , Nihar Ranjan Rout
Background
Aging is a heterogeneous process, and older adults are at greater risk of experiencing physical and functional health challenges. This study examines the comparative prevalence of diabetes-related disability among older adults in West Bengal and India.
Methods
Data were drawn from the first wave of the Longitudinal Aging Study in India (2017–18), comprising 72,250 individuals aged 45 years and above, including 3933 respondents from West Bengal. A multistage stratified sampling method was used. Functional disability was assessed using six Activities of Daily Living (ADL) and seven Instrumental Activities of Daily Living (IADL). Logistic regression was used to assess the association between diabetes and disability, and the Blinder–Oaxaca decomposition technique was applied to identify the contribution of various factors to the observed differences.
Results
The prevalence of ADL and IADL difficulties among older adults with diabetes was 24.1 % in West Bengal and 18.9 % at the national level. The risk of disability among diabetic elderly was significantly higher in West Bengal [OR = 6.20 (3.74–10.26) for ADL; OR = 6.71 (4.69–9.61) for IADL] compared to India [OR = 3.92 (1.10–14.03) for ADL; OR = 3.91 (1.17–13.12) for IADL]. Decomposition analysis showed that comorbidity factors accounted for 37 % of the ADL/IADL disability gap between West Bengal and India.
Conclusion
Nearly one-fourth of older adults with diabetes in West Bengal experience ADL limitations. There is urgent need to enhance healthcare services for individuals in West Bengal who are face higher levels of diabetes and disability.
{"title":"Prevalence of diabetes and disability among older adults in West Bengal and India: A comparative analysis","authors":"Ujjwal Das , Nishamani Kar , Tomo Riba , Nihar Ranjan Rout","doi":"10.1016/j.dsx.2025.103236","DOIUrl":"10.1016/j.dsx.2025.103236","url":null,"abstract":"<div><h3>Background</h3><div>Aging is a heterogeneous process, and older adults are at greater risk of experiencing physical and functional health challenges. This study examines the comparative prevalence of diabetes-related disability among older adults in West Bengal and India.</div></div><div><h3>Methods</h3><div>Data were drawn from the first wave of the Longitudinal Aging Study in India (2017–18), comprising 72,250 individuals aged 45 years and above, including 3933 respondents from West Bengal. A multistage stratified sampling method was used. Functional disability was assessed using six Activities of Daily Living (ADL) and seven Instrumental Activities of Daily Living (IADL). Logistic regression was used to assess the association between diabetes and disability, and the Blinder–Oaxaca decomposition technique was applied to identify the contribution of various factors to the observed differences.</div></div><div><h3>Results</h3><div>The prevalence of ADL and IADL difficulties among older adults with diabetes was 24.1 % in West Bengal and 18.9 % at the national level. The risk of disability among diabetic elderly was significantly higher in West Bengal [OR = 6.20 (3.74–10.26) for ADL; OR = 6.71 (4.69–9.61) for IADL] compared to India [OR = 3.92 (1.10–14.03) for ADL; OR = 3.91 (1.17–13.12) for IADL]. Decomposition analysis showed that comorbidity factors accounted for 37 % of the ADL/IADL disability gap between West Bengal and India.</div></div><div><h3>Conclusion</h3><div>Nearly one-fourth of older adults with diabetes in West Bengal experience ADL limitations. There is urgent need to enhance healthcare services for individuals in West Bengal who are face higher levels of diabetes and disability.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 4","pages":"Article 103236"},"PeriodicalIF":4.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143918262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.dsx.2025.103229
Ningjian Wang , Anoop Misra
{"title":"Highlights of the current issue","authors":"Ningjian Wang , Anoop Misra","doi":"10.1016/j.dsx.2025.103229","DOIUrl":"10.1016/j.dsx.2025.103229","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103229"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Individuals with schizophrenia are at high risk of developing type 2 diabetes. This study aimed to develop a tailored solution to address their complex diabetes care needs, based on insights from patients and healthcare professionals, to enhance self-care.
Methods
Using a Participatory Design approach, we conducted three workshops and an evaluation, which included focus groups, interviews, and written feedback. Patients, healthcare professionals, and stakeholders actively participated in all stages of the process between May 2022 and December 2023. Iterative processes ensured comprehensive input in idea generation and concept development. Data analysis followed the steps of planning, acting, observing, and reflecting. The study is reported using SRQR framework.
Results
Participants highlighted challenges such as navigating a fragmented healthcare system, undertreatment, and stigma. In response, a tailored educational manual for voluntary mentors was developed. This two-day training program equips mentors to support individuals with type 2 diabetes and schizophrenia, fostering collaboration and bridging the gap between psychiatric and somatic care.
Conclusions
A co-designed approach may enhance diabetes self-care and improve coordination between healthcare sectors.
{"title":"Collaborative innovations in diabetes self-care for individuals with type 2 diabetes and schizophrenia: A Participatory Design study developing a diagnosis-specific educational manual","authors":"Tanja Juhl Mikkelsen , Dorte Moeller Jensen , Elsebeth Stenager , Mette Juel Rothmann","doi":"10.1016/j.dsx.2025.103220","DOIUrl":"10.1016/j.dsx.2025.103220","url":null,"abstract":"<div><h3>Background and aims</h3><div>Individuals with schizophrenia are at high risk of developing type 2 diabetes. This study aimed to develop a tailored solution to address their complex diabetes care needs, based on insights from patients and healthcare professionals, to enhance self-care.</div></div><div><h3>Methods</h3><div>Using a Participatory Design approach, we conducted three workshops and an evaluation, which included focus groups, interviews, and written feedback. Patients, healthcare professionals, and stakeholders actively participated in all stages of the process between May 2022 and December 2023. Iterative processes ensured comprehensive input in idea generation and concept development. Data analysis followed the steps of planning, acting, observing, and reflecting. The study is reported using SRQR framework.</div></div><div><h3>Results</h3><div>Participants highlighted challenges such as navigating a fragmented healthcare system, undertreatment, and stigma. In response, a tailored educational manual for voluntary mentors was developed. This two-day training program equips mentors to support individuals with type 2 diabetes and schizophrenia, fostering collaboration and bridging the gap between psychiatric and somatic care.</div></div><div><h3>Conclusions</h3><div>A co-designed approach may enhance diabetes self-care and improve coordination between healthcare sectors.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103220"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.1016/j.dsx.2025.103204
Jiaxi Zhao , Rong Chen , Mengqi Luo , Quanjing Zhu , Qian Zhao
Aim
Antihyperglycemic drugs have potential therapeutic benefits for inflammatory bowel disease (IBD). We aimed to investigate the association between genetic variations in gene-targeted antihyperglycemic drugs and the risk of IBD.
Methods
Summary statistics for HbA1c data were from the UK Biobank including 344,182 participants. Statistics of IBD were obtained from UK Inflammatory Bowel Disease Genetics. Two Mendelian randomization methods were employed to derive the main findings.
Results
In the SMR analysis, increased expression of genetic variations in SGLT2 inhibitor targets (gene: SLC5A2) was linked to a higher risk of CD (OR: 1.97, P = 0.048). Genetic variation in brain cerebellum tissue of sulfonylurea targets (gene: ABCC8) expression was positively associated with IBD (OR = 1.11, P = 0.000). The genetic variation in the GLP-1RA targets (gene: GLP1R) expression was positively correlated with IBD (OR: 1.45, P = 0.039). The IVW-MR analysis suggested reduced IBD and CD risk with expression of increased genetic variation in the thiazolidinediones targets (gene: PPARG).
Conclusion
Genetic variations in SGLT2 inhibitor targets might be associated with an increased risk of CD. The ABCC8 gene might be linked to IBD, CD, and UC. There might be a positive correlation between genetic variation in the GLP-1RA targets expression and IBD occurrence.
目的降血糖药物对炎症性肠病（IBD）具有潜在的治疗效果。我们的目的是研究基因靶向降糖药物的遗传变异与IBD风险之间的关系。方法HbA1c数据汇总统计来自UK Biobank，包括344,182名参与者。IBD的统计数据来自英国炎症性肠病遗传学。采用两种孟德尔随机化方法得出主要研究结果。结果在SMR分析中，SGLT2抑制剂靶点（基因：SLC5A2）基因变异的表达增加与更高的CD风险相关（OR: 1.97, P = 0.048）。磺酰脲靶基因ABCC8在脑小脑组织中的表达与IBD呈正相关（OR = 1.11, P = 0.000）。GLP-1RA靶点（基因：GLP1R）表达的遗传变异与IBD呈正相关（OR: 1.45, P = 0.039）。IVW-MR分析表明，噻唑烷二酮靶基因（基因：PPARG）的遗传变异表达增加，IBD和CD风险降低。结论SGLT2抑制剂靶点的遗传变异可能与CD风险增加有关，ABCC8基因可能与IBD、CD和UC有关。GLP-1RA靶点表达的遗传变异可能与IBD的发生呈正相关。
{"title":"Genetic variation in targets of antihyperglycemic drugs and inflammatory bowel disease’ risk: A mendelian randomization study","authors":"Jiaxi Zhao , Rong Chen , Mengqi Luo , Quanjing Zhu , Qian Zhao","doi":"10.1016/j.dsx.2025.103204","DOIUrl":"10.1016/j.dsx.2025.103204","url":null,"abstract":"<div><h3>Aim</h3><div>Antihyperglycemic drugs have potential therapeutic benefits for inflammatory bowel disease (IBD). We aimed to investigate the association between genetic variations in gene-targeted antihyperglycemic drugs and the risk of IBD.</div></div><div><h3>Methods</h3><div>Summary statistics for HbA1c data were from the UK Biobank including 344,182 participants. Statistics of IBD were obtained from UK Inflammatory Bowel Disease Genetics. Two Mendelian randomization methods were employed to derive the main findings.</div></div><div><h3>Results</h3><div>In the SMR analysis, increased expression of genetic variations in SGLT2 inhibitor targets (gene: SLC5A2) was linked to a higher risk of CD (OR: 1.97, <em>P</em> = 0.048). Genetic variation in brain cerebellum tissue of sulfonylurea targets (gene: ABCC8) expression was positively associated with IBD (OR = 1.11, <em>P</em> = 0.000). The genetic variation in the GLP-1RA targets (gene: GLP1R) expression was positively correlated with IBD (OR: 1.45, <em>P</em> = 0.039). The IVW-MR analysis suggested reduced IBD and CD risk with expression of increased genetic variation in the thiazolidinediones targets (gene: PPARG).</div></div><div><h3>Conclusion</h3><div>Genetic variations in SGLT2 inhibitor targets might be associated with an increased risk of CD. The ABCC8 gene might be linked to IBD, CD, and UC. There might be a positive correlation between genetic variation in the GLP-1RA targets expression and IBD occurrence.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103204"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号